Johnson & Johnson lined up a $785 million upfront option deal to work with Sail Biomedicines, part of Flagship Pioneering, on in vivo CAR-T approaches. The transaction structure calls for J&J to pay $785 million upfront and provides additional economics tied to milestones, according to the report. The deal expands J&J’s footprint in a cell-therapy category increasingly competitive around in vivo delivery—where engineered immune function is intended to be created after administration rather than built ex vivo. For investors and developers, the key element is strategic option exposure: J&J is buying into a platform stage while keeping commercial flexibility as efficacy and safety data mature. If the collaboration yields durable clinical signals, the approach could shift how CAR-T manufacturing and logistics scale across indications.